Theratechnologies Inc T.TH

Time for action

[Trogarzon]

Since this management has'nt provided a normal liquidity and decent valuation for the company shares, I am asking Soleus and others to pull together to draw some serious action from the BOD... total mess for shareholders... no way out.  How do you sell 1m shares without hitting the bid at 20 cents..

[qwerty22]

We've found our leader!  

[Trogarzon]

No but seriously, when have you heard Paul talk about how they are going to drive the price of shares higher using something else than the mind boggling comment.  I want a roadmap with details and timeframe, deliverables... otherwise just go and put in place a strategic review plan.

[realitycheck4u]

This post has been removed in accordance with Community Policy

[SPCEO1]

There is almost no short position on THTX so it may be worth considering that Trogarzon is just trying to scare others into selling him more shares on the cheap before big positive news. Given the tiny volume, it does not appear to be a strategy that is working very well (at least from a trading volume perspective) if it is even his strategy. It seems clear that those who own the stock are holding

[qwerty22]

It's really not great timing though. If we take what juniper said about 3 SD patients. Even though they are fine, they aren't reportable. SD after 2 cycles is not something you can chalk up to the drugs effect. They might get their next scan in the coming weeeks which at best would deliver an unconfirmed response and then it's 2 more cycles(6 weeks) to the next scan before there is the

[scarlet1967]

I put an article published in China "nicked"!The never ending issue with THTX is lack of coverage so my point wasn't so much the content of the article but exposure it can create. First they have to create that exposure then they can materialize on the audience the exposure brings so any meaningful progress communicated by the company creates  the buzz it deserves among

[Wino115]

Any thing based off scans it does appear it would be the latter time frame.  When I look at the various charts they posted with pre clinical dose and timelines measuring tumor burden, other than melanoma, the other 3 charts show minimal declines with first two,doses and then it starts in earnest.  Melanoma starts a bit earlier.  The caveat is they are not log charts, they are linear

[SPCEO1]

Juniper88, whose background is admittedly in finance and not medicine did report a quick decline in the CA-125 test after just one cycle of treatment and observed with the naked eye as well as through her final scan after 2 cycles of treatment and 4-5 weeks in the study, some tumors shrink meaningfully. I find that pretty encouraging as the drug clearly works at some level for ovarian cancer

[longterm56]

Another thing about Juniper88's wife (bless her soul) ... she, like all others, received the "standard dose" ...  even though her body is overwhelmed with cancerous tissue. So ... how does this standard dose distribute across *numerous* tumors? Does the majority go to the first one(s) it encounters or is it evenly distributed across the many.  This might explain why some

[realitycheck4u]

This post has been removed in accordance with Community Policy

[SPCEO1]

In the pre-clinical work, the dosage was likely more calibrated witht he tumor it was attacking and also was likely only attacking one tumor. Human trials are dealing with a whole lot of variables not seen in the pre-clinical work.  Also, could some of the tumors that did not react have been younger tumors that did not overexpress sortilin?